Switching test from cinalcalcet to etelcalcetide in secondary hyperpapathyroidism patients ongoing hemodialysis

Switching test from cinalcalcet to etelcalcetide in secondary hyperpapathyroidism patients ongoing hemodialysis - Switching test from cinalcalcet to etelcalcetide

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000033514

Enrollment

Registered

2018-08-01

Start date

2017-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Secondary hyperpapathyroidism

Interventions

From the day after cinacalcet discontinuation, etelcalcetide was intravenously injected bolus three times a week for 12 months at the end of each dialysis. The initial dose for intravenous injection w

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Three weekly hemodialysis patients of secondary hyperparathyroidism who are orally taking Cinacalcet.

Exclusion criteria

Exclusion criteria: Patients with malignant tumors

Design outcomes

Primary

Measure	Time frame
Noninferiority of etelcalcetide to cinacalcet on serum parathyroid hormone suppression after 12 months	—

Secondary

Measure	Time frame
Evaluation of safety of etelcalcetide, especially including hypocalcemia	—

Countries

Japan

Contacts

Public ContactRyoichi Miyazaki

Fujita Memorial Hospital Department of Internal Medicine

ryoichi@mitene.or.jp0776-21-1277

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026